Medicine
Ropivacaine 150 mg/30 mL injection
Ropivacaine 150 mg/30 mL injection is a generic prescription medicine for epidural, infiltration, perineural use, made by 11 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Solutions should be stored at 20 °C to 25 °C (68 °F to 77 °F).
Key facts
- Active ingredient (INN)
- Ropivacaine
- Brand
- Sold under the generic name
- Strength
- 150 mg/30 mL
- Dosage form
- Injection
- Route
- Epidural, infiltration, perineural
- Packs
- 5 vials of 30 mL, 25 vials of 30 mL, 10 vials of 30 mL and 15 more
- Manufacturers
- Anthea PharmaIndiaGlenmark PharmaceuticalsIndiaCaplin SterilesIndiaEugiaIndiaSomerset TherapeuticsSportpharmArmas PharmaceuticalsBaxter HealthcareCivicaMeitheal Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Solutions should be stored at 20 °C to 25 °C (68 °F to 77 °F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 15 September 2016
- Identifiers
- RxCUI 1734084, 1734207, 1734475 +6DailyMed set ID 781d4b7f-7556-4695-8d48-7772d7a0d8e9, ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64, f2b54355-a596-4f97-aeaa-d93e3984c42d +9NDC 43066-023, 70069-064, 83854-014 +9Application ANDA212808, ANDA207636, ANDA219883 +2
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 5 vial in 1 carton / 30 mL in 1 vial | 83854-014-05 | Anthea PharmaIndia | 21 March 2025 |
| 25 vial in 1 carton / 30 mL in 1 vial | 83854-014-06 | Anthea PharmaIndia | 21 March 2025 |
| 10 vial in 1 carton / 30 mL in 1 vial | 83854-014-10 | Anthea PharmaIndia | 21 March 2025 |
| 10 vial in 1 carton / 30 mL in 1 vial | 65145-109-10 | Caplin SterilesIndia | 24 June 2025 |
| 25 vial, single-dose in 1 carton / 30 mL in 1 vial, single-dose | 55150-198-30 | EugiaIndia | 15 September 2016 |
| 25 vial in 1 carton / 30 mL in 1 vial | 68462-794-62 | Glenmark PharmaceuticalsIndia | 7 August 2025 |
| 10 vial in 1 carton / 30 mL in 1 vial | 68462-794-84 | Glenmark PharmaceuticalsIndia | 7 August 2025 |
| 10 vial, single-dose in 1 carton / 30 mL in 1 vial, single-dose | 72485-519-10 | Armas Pharmaceuticals | 1 June 2026 |
| 10 vial in 1 carton / 30 mL in 1 vial | 43066-023-10 | Baxter Healthcare | 9 April 2020 |
| 25 vial, single-dose in 1 carton / 30 mL in 1 vial, single-dose | 71288-735-31 | Meitheal Pharmaceuticals | 30 July 2024 |
| 1 vial in 1 carton / 30 mL in 1 vial | 70069-064-01 | Somerset Therapeutics | 15 June 2018 |
| 10 vial in 1 carton / 30 mL in 1 vial | 70069-064-10 | Somerset Therapeutics | 20 December 2021 |
| 25 vial in 1 carton / 30 mL in 1 vial | 70069-064-25 | Somerset Therapeutics | 20 December 2021 |
| 1 vial in 1 carton / 30 mL in 1 vial | 85766-097-30 | Sportpharm | 8 October 2025 |
| 1 vial, single-dose in 1 carton / 30 mL in 1 vial, single-dose | 85766-098-01 | Sportpharm | 15 October 2025 |
| 25 vial, single-dose in 1 carton / 30 mL in 1 vial, single-dose | 85766-098-25 | Sportpharm | 15 October 2025 |
| 10 vial, single-dose in 1 carton / 30 mL in 1 vial, single-dose | 72572-707-10 | Civica | 19 September 2022 |
| 30 mL in 1 vial | 84549-164-25 | ProPharma Distribution | 10 October 2025 |
| 10 vial, single-dose in 1 carton / 30 mL in 1 vial, single-dose | 0143-9264-10 | — | 18 November 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 24 September 1996 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Ropivacaine 150 mg/30 mL injection.
Other strengths and forms of Ropivacaine
Clinical summary
Ropivacaine is an amide local anesthetic indicated for the production of local or regional anesthesia for surgery and for acute pain management. It is available as injection for epidural, infiltration and perineural use. MedsAcross supplies Ropivacaine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RopivacaineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Naropin prescribing information (Fresenius Kabi) · U.S. National Library of Medicine, DailyMed
Need Ropivacaine 150 mg/30 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.